Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Summary
This study looks at how well and how safe fluticasone propionate nebulized suspension works in babies aged 0 to 24 months who have acute wheezing. Investigators will compare it to budesonide nebulized suspension, another approved inhaled steroid. About 240 babies will join. Participants will be put into two groups by chance (1:1 randomization): One group gets fluticasone propionate 0.5 mg twice a day by nebulizer The other group gets budesonide 1 mg twice a day by nebulizer Treatment lasts 5 to 7 days. Investigators will check breathing symptoms (wheezing, cough, phlegm, wheeze sounds in lungs) every day during treatment. The study will check if fluticasone works as well as budesonide (non-inferiority) and may also check if it works better. Safety will be watched closely, including side effects, general health, and lab tests. This study will help doctors know if fluticasone propionate nebulized suspension is a good treatment option for young babies with wheezing.
Official title: A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
Key Details
Gender
All
Age Range
0 Months - 24 Months
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2026-08-01
Completion Date
2027-06-30
Last Updated
2026-06-30
Healthy Volunteers
No
Interventions
Fluticasone Propionate Nebulization
0.5mg/2ml, BID
Budesonide Nebulization
1mg/2ml, BID